



14 January 2026  
EMA/CVMP/ERA/291857/2025-Corr.\*  
Committee for Veterinary Medicinal Products (CVMP)

## Work plan for the Committee for Veterinary Medicinal Products (CVMP) Environmental Risk Assessment Working Party (ERAWP) 2026

<b>Chairpersons:</b>	<b>Status</b>
Chair: M. Montforts Vice-chair: I. de la Casa	Adopted by CVMP in December 2025

*The activities outlined in the work plan for 2026 have been agreed considering the respective business priorities and may be subject to further review and reprioritisation in accordance with the business plan of the Agency.*

### 1. Meetings scheduled for 2026

<b>Plenary meetings:</b>	3 (per meeting: Chair plus 10–12 members, 2 days) 24–25 February 2026 (virtual) 3–4 June 2026 (in person) 13–14 October 2026 (virtual)
<b>Other meetings:</b>	
Drafting/expert groups	10–15 meetings (mostly virtual; approximately 7–10 participants per meeting)
Workshop/focus group	1 (related to the development of a guideline on the environmental risk assessment of parasitocidal veterinary medicinal products for cats and dogs)
Training	None

\* The word 'parasitocidal' was replaced with the word 'ectoparasitocidal' in the title of item 3.2.1.



If feasible and depending on the circumstances, some of the plenary meetings could be replaced by virtual meetings. Drafting/expert group meetings are mainly regarded as complementary to plenary meetings.

## 2. Product-related issues

The following table provides the expected number per year of contributions (number of involvements in dossier) for scientific advice and product assessment, including pre- and post-authorisation issues.

Expected contribution in scientific advice	Expected contribution in product assessment
0	1

## 3. CVMP guidance documents

### 3.1. Guidance documents to be finalised after the consultation period

#### 3.1.1. All published guidance documents within the remit of the ERAWP

**Action:** Update of relevant guidance documents in order to align them with provisions outlined in Regulation (EU) 2019/6, as applicable.

**Priority 3.** Start date: ongoing, completion date: June 2026.

**Comments:** None.

### 3.2. Guidance documents to be released for consultation

#### 3.2.1. Development of a guideline on the methodology of environmental risk assessment for ectoparasitocidal VMPs for cats and dogs

**Action:** Consider the comments received during the public consultation of the concept paper and agree next steps with CVMP.

**Priority 2.** Start date: Q1 2026, completion date: beyond 2026.

**Comments:** None.

#### 3.2.2. Development of a guideline on the environmental risk assessment of veterinary medicinal products intended for use in aquaculture

**Action:** Work on the guideline to be continued.

**Priority 2.** Start date: ongoing, completion date: beyond 2026.

**Comments:** This item is linked to action 5.3.1.b of the 'European Union Strategic Approach to Pharmaceuticals in the Environment' (COM[2019] 128 final). Final draft for public consultation expected for Q2 2026.

#### 3.2.3. Development of a reflection paper on the assessment of public health risks related to antimicrobial resistance acquired via the environment, resulting from the use of a VMP

**Action:** Work on the reflection paper to be initiated.

**Priority 2.** Start date: Q1 2026, completion date: beyond 2026.

**Comments:** Activity to be performed in consultation with the AWP.

### **3.2.4. Reflection paper on risk mitigation measures related to the environmental risk assessment of veterinary medicinal products (EMA/CVMP/ERAWP/409328/2010)**

**Action:** Review of the reflection paper to include reference to the newest applicable legislation (e.g. Regulation (EU) 2019/6) as well as critical review of the adequacy/appropriateness of risk mitigation measures formulated/applied since the paper's initial release in 2012.

**Priority 2.** Start date: ongoing, completion date: Q2 2026.

**Comments:** None.

### ***3.3. New topics/concept papers to be prepared***

#### **3.3.1. Consider the need for a revision of the 'Reflection paper on the interpretation of Article 18(7) of Regulation (EU) 2019/6' (EMA/CVMP/ERA/622045/2020)**

**Action:** Work on the revision of the reflection paper to be initiated.

**Priority 3.** Start date: ongoing, completion date: Q4 2026.

**Comments:** Activity to be performed by a dedicated expert group.

## **4. VICH Guidelines and activities**

None.

## **5. EU regulatory activities**

### ***5.1. Collaboration with EFSA***

**Actions:** Provide contribution to EFSA opinions in accordance with Article 59 of Regulation (EC) No 726/2004, as required.

Consultations and cooperation with the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) on environmental risk assessment issues, as required.

**Comments:** None.

### ***5.2. Collaboration with ECHA***

**Action:** Consultation with the 'ECHA PBT Working Group' and with the 'Biocidal Products Committee (BPC) Working Group — Environment', as required.

**Comments:** None.

### **5.3. Assessors training**

**Actions:** Provide advice/active participation for training of assessors, as required.

**Comments:** None.

### **5.4. Other**

**Actions:** Provide advice to the EC and other EU Agencies on issues of mutual interest with regard to environmental risk assessment, as required.

Provide contributions to guidelines and questions raised by other working parties and *ad hoc* expert groups, as required.

Provide advice to the CVMP on questions relating to environmental risk assessment arising from referral procedures, as required.

Elaborate an EU-NTC veterinary environmental risk assessment sub-curriculum. This will direct work to increase capability in modelling, simulation and extrapolation within the European Regulatory Network (with applications in environmental fate and ecotoxicological assessment), for example, by seeking out and developing relevant training materials.

**Comments:** None.

## **6. Activities with external parties**

### **6.1. Meetings with interested parties**

None foreseen.

### **6.2. Regulatory authorities outside the EU**

None foreseen.

## **7. Organisational matters**

### **7.1. List of adopted organisational documents**

Mandate, objectives, and rules of procedure for working parties under the quality, non-clinical, methodology, clinical and veterinary domains (EMA/299541/2025).

### **7.2. List of organisational documents to be developed/revised in the forthcoming 2 years**

None.

### **7.3. List of proposed scientific guidelines for the next work plan<sup>†</sup>**

None.

---

<sup>†</sup> The actual items to be included in ERAWP work plan for 2027 will be considered and agreed by the CVMP.